Cytek (CTKB) Director Michael Exercises 2,181 RSUs

What Happened

• Director Michael (Cytek Biosciences, CTKB) reported the conversion/exercise of 2,181 derivative units (code M) on August 18, 2026. The filing shows 2,181 shares were acquired via conversion of RSUs (acquisition price not reported) and 2,181 shares were disposed the same day at $0.00 (proceeds $0).
• This transaction reflects a conversion of Restricted Stock Units (RSUs) rather than an open-market purchase or sale for cash.

Key Details

• Transaction date: 2026-08-18. Form 4 filed: 2026-08-20 (appears timely).
• Transaction codes: M = exercise/conversion of derivative security.
• Shares converted/acquired: 2,181 (acquisition price not stated). Shares disposed: 2,181 at $0.00 (proceeds $0).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU represents a contingent right to one share. F2 — the RSU award vests over three years on a specified schedule (detailed vesting fractions and dates in the filing).
• The filing does not explicitly state the reason for the $0.00 disposition.

Context

• Converting RSUs into shares is a routine administrative step when RSUs vest. The same-day disposal at $0.00 is commonly used to satisfy tax withholding obligations rather than representing an open-market sale, but the Form 4 does not explicitly say that here.
• For retail investors: this is an insider converting vested compensation into shares and appears administrative in nature; it is not necessarily a signal of buying or selling conviction.